AVA6000 is a novel form of doxorubicin that has been modified using Avacta’s delivery platform to improve safety
from PharmaTimes: News RSS https://ift.tt/zAIbkZ5
Post Top Ad
Wednesday, 29 June 2022
Avacta announces escalation in clinical study of AVA6000
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment